




Efferon[®] NEO

Next-generation hemoadsorption
for the most fragile patients

CE marked under
the EU MDR



Designed and Manufactured
in the European Union



Next-generation hemoadsorption
device for endotoxin and cytokine
removal



For patients with lower circulating
blood volume



For isolated hemoadsorption
or in combination with RRT,
ECMO/CPB



Blood priming volume,
30 mL




Approved for sepsis
and septic shock

Pediatric sepsis remains a critical challenge

Children with sepsis are among the most vulnerable ICU patients.

MECHANISM OF ACTION:

Endotoxins are bound due to interaction with surface-immobilized LPS-selective ligand



40%

all sepsis cases worldwide occur in children under 5 years of age

20M

cases of sepsis annually

Effective modulation of systemic inflammation is **essential** to improve outcomes.




CLINICAL EVIDENCE: LASSO NEO MULTICENTER STUDY

ClinicalTrials.gov
ID NCT05707494

STUDY DESIGN:


- > 8 study centers
- > 78 pediatric patients (32 HA vs 46 historical control)
- > Hemoadsorption x 2 sessions/18 hours total

Reduction of inflammatory markers by day 2




Earlier weaning from organ support

Recovery from Mechanical Ventilation



Lower pSOFA score by day 7



MAIN OUTCOMES:

Lower 28-day mortality
(p = 0.008, OR = 0.2)

9%

with Efferon NEO

35%

in control

Vasopressor/inotropic support

